NCT02278315View on ClinicalTrials.gov

Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

December 9, 2020

Study Completion Date

August 10, 2022

Conditions
Multiple Myeloma
Interventions
DRUG

I-131-CLR1404

Single IV dose of I-131-CLR1404, increased/decreased by cohort

DRUG

dexamethasone

40 mg dexamethasone orally once weekly for up to 12 weeks

DRUG

I-131-CLR1404

Multiple IV dose of I-131-CLR1404, increased/decreased by cohort

Trial Locations (4)

32224

Mayo Clinic, Jacksonville

48201

Karmanos Cancer Institute, Detroit

53792

University of Wisconsin Hospital and Clinics, Madison

60153

Loyola University Medical Center, Maywood

Sponsors
All Listed Sponsors
lead

Cellectar Biosciences, Inc.

INDUSTRY